Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines.
The in vitro anticryptosporidial activities of ranalexin, lasalocid and azithromycin alone and in combination were investigated against four clinical isolates of Cryptosporidium parvum. Susceptibility was tested by inoculating the isolates on to cell monolayers and determining the parasite count after 48 h incubation at 37 degrees C. The culture medium was supplemented with Dulbecco's modified Eagle's medium containing serial dilutions of the above-mentioned compounds. Ranalexin showed moderate anticryptosporidial activity: at a concentration of 64 mg/L it reduced parasite counts by 33.8%. Azithromycin at a concentration of 8 mg/L gave inhibition comparable to that observed with the highest concentration of ranalexin. Lasalocid showed the highest activity, with a 70.3% reduction in parasite counts at 2 mg/L. The combination of ranalexin 64 mg/L and lasalocid 2 mg/L completely suppressed parasite growth without harming the monolayer.
Giacometti
A
A
Institute of Infectious Diseases and Public Health, University of Ancona, Italy.
Cirioni
O
O
Barchiesi
F
F
Scalise
G
G
D000163:Acquired Immunodeficiency Syndrome / Q000469:parasitology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology*; D002478:Cells, Cultured; D003049:Coccidiostats / Q000494:pharmacology*; D016785:Cryptosporidium parvum / Q000187:drug effects*; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D005243:Feces / Q000469:parasitology; D006801:Humans; D007832:Lasalocid / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D003049:Coccidiostats; D010456:Peptides, Cyclic; C086618:ranalexin; D017963:Azithromycin; D007832:Lasalocid